Value £50,000,000

NRG Therapeutics

VC Funding

Series B £50m+

Healthcare & Biotech Published 9 September 2025

Summary

In a significant market movement during September 2025, NRG Therapeutics was the subject of a vc funding. The transaction achieved a gross valuation of £50,000,000. Leading the round was Novartis Venture Fund, SV Health Investors’ Dementia Discovery Fund (DDF), Brandon Capital, Omega Funds, British Business Bank, Criteria Bio Ventures, M Ventures.

This transaction was brokered by an undisclosed advisor. The deal reflects ongoing market confidence within its sector.

Lead Investor / Acquirer

Novartis Venture Fund

Lead Investor / Acquirer

SV Health Investors’ Dementia Discovery Fund (DDF)

Lead Investor / Acquirer

Brandon Capital

Lead Investor / Acquirer

Omega Funds

Lead Investor / Acquirer

British Business Bank

Lead Investor / Acquirer

Criteria Bio Ventures

Lead Investor / Acquirer

M Ventures

Advising Broker

Undisclosed Firm

Related Deals in Healthcare & Biotech

Series B prioritised

VC Funding

Evaro

£18,000,000

Jan 2026

VC Funding

Kraken Technologies

£25,000,000

Jan 2026

VC Funding

Scan.com

£67,220,000

Sept 2026

VC Funding

Ternary Therapeutics

£3,600,000

Mar 2026

View Company Details

Financials, officers, full deal history

Original Source

This funding round is sourced from the Tech.eu Funding Explorer. View the full record, investors, and citations there.

View on Tech.eu Funding Explorer

Funding data via Tech.eu Funding Explorer, licensed under CC BY 4.0. See our methodology.

AI Insight Lenses

Pro

AI-generated analysis from four professional perspectives. Powered by PE Deals.

Free to all registered users.